Comparative effectiveness research for antipsychotic medications: how much is enough?
- PMID: 19622539
- PMCID: PMC3242475
- DOI: 10.1377/hlthaff.28.5.w794
Comparative effectiveness research for antipsychotic medications: how much is enough?
Abstract
Second-generation antipsychotics have attracted practitioners' and policy-makers' attention, because of concerns over their health effects and costs. Comparative effectiveness data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-a high-profile National Institutes of Health (NIH)-funded study-have been used to argue for restricting coverage for these costly drugs. But concerns about the design of CATIE and its associated cost-effectiveness analysis and uncertainty about the precision of these findings raise questions about this interpretation. Our work suggests that additional research to increase the precision of comparisons of the effectiveness of antipsychotics would be well worth the cost.
Figures
Similar articles
-
Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.J Comp Eff Res. 2012 Mar;1(2):171-80. doi: 10.2217/cer.12.8. J Comp Eff Res. 2012. PMID: 24237376 Free PMC article.
-
Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.J Clin Psychiatry. 2007 Feb;68(2):e05. doi: 10.4088/jcp.0207e05. J Clin Psychiatry. 2007. PMID: 17335313
-
Developing a policy for second-generation antipsychotic drugs.Health Aff (Millwood). 2009 Sep-Oct;28(5):w782-93. doi: 10.1377/hlthaff.28.5.w782. Epub 2009 Jul 21. Health Aff (Millwood). 2009. PMID: 19622538
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.J Clin Psychiatry. 2007 Feb;68(2):e04. doi: 10.4088/jcp.0207e04. J Clin Psychiatry. 2007. PMID: 17335312 Review.
-
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.Can J Psychiatry. 2010 Mar;55(3):117-25. doi: 10.1177/070674371005500302. Can J Psychiatry. 2010. PMID: 20370961 Review.
Cited by
-
Quantitative Methods for Valuing Comparative Effectiveness Information.Biopharm Rep. 2010 Fall;17(2):2-10. Biopharm Rep. 2010. PMID: 24455754 Free PMC article. No abstract available.
-
Heterogeneity in action: the role of passive personalization in comparative effectiveness research.Health Econ. 2014 Mar;23(3):359-73. doi: 10.1002/hec.2996. Epub 2013 Oct 9. Health Econ. 2014. PMID: 24123568 Free PMC article.
-
Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?Pharmacoeconomics. 2010;28(10):855-65. doi: 10.2165/11538640-000000000-00000. Pharmacoeconomics. 2010. PMID: 20831293
-
The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.Pharmacoeconomics. 2010;28(10):843-53. doi: 10.2165/11539400-000000000-00000. Pharmacoeconomics. 2010. PMID: 20831292 Free PMC article.
References
-
- Tandon R, Fleischhacker WW. Comparative Efficacy of Antipsychotics in the Treatment of Schizophrenia: A Critical Assessment. Schizophrenia Research. 2005;79(2–3):145–155. - PubMed
-
- This paper uses the commonly used terms “first-generation antipsychotics” and “second-generation anti-psychotics,” which are sometimes called “typical” and “atypical” antipsychotic drugs H.Y Meltzer, “Atypical Antipsychotic Drugs Have Their Merits. Lancet. 2009;373(9668):1007. - PubMed
-
- Kane JM. Tardive Dyskinesia Rates with Atypical Antipsychotics in Adults: Prevalence and Incidence. Journal of Clinical Psychiatry. 2004;65(9 Supp):16–20. - PubMed
-
-
We excluded clozapine because of its risk of causing dangerously low white blood cell counts (agranulocytosis), which has limited its approved use for patients who do not respond sufficiently to treatment with other antipsychotic drugs or who cannot tolerate the drug’s greater potential to cause movement disorders.
-
-
- Kahn RS, et al. Effectiveness of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreni-form Disorder: An Open Randomised Clinical Trial. Lancet. 2008;371(9618):1085–1097. - PubMed
- Meltzer HY. Focus on the Metabolic Consequences of Long-Term Treatment with Olanzapine, Quetiapine and Risperidone: Are There Differences? International Journal of Neuropsychopharmacology. 2005;8(2):153–156. - PubMed
- Woodward ND, et al. A Meta-Analysis of Neuropsychological Change to Clozapine, Olanzapine, Quetiapine, and Risperidone in Schizophrenia. International Journal of Neuropsychopharmacology. 2005;8(3):457–472. - PubMed
- Lagnado L. Prescription Abuse Seen in U.S. Nursing Homes. Wall Street Journal. 2007 December;4
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
